![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
JL Ellis and BJ Undem
Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland.
The site of action of resiniferatoxin (RTX) and capsaicin and the pharmacological consequences of the resultant tachykinin release were examined in the guinea pig trachea. RTX and capsaicin were both potent and efficacious contractors of isolated tracheal smooth muscle. RTX was about 20-fold more potent than capsaicin, with -log (M) EC50 values of 8.88 +/- 0.09 (n = 14) and 7.55 +/- 0.07 (n = 14), respectively. The putative capsaicin receptor antagonist capsazepine (10 microM) effectively inhibited responses to both RTX and capsaicin in a competitive fashion. The -log (M) pKB values for capsazepine against resiniferatoxin and capsaicin were 6.28 +/- 0.25 and 6.04 +/- 0.13, respectively. Contractile responses to RTX and capsaicin were unaffected by the NK-1 antagonist CP 96345 (0.3 microM), partially inhibited by the NK-2 antagonist SR 48968 (0.3 microM) but nearly abolished by a combination of the antagonists. Capsaicin and RTX desensitized tissues to subsequent additions of either capsaicin (1 microM) or RTX (0.1 microM). Capsaicin showed maximal desensitization at 1 microM, and RTX at 0.1 microM. This study shows that RTX is a potent activator of capsaicin-sensitive tachykinin-containing nerves in the airways. The site of action of RTX and capsaicin appears to be a receptor sensitive to capsazepine. Moreover, RTX and capsaicin both release tachykinins that act on both NK-1 and NK-2 receptor subtypes.
This article has been cited by other articles:
|
|
 |
|
  T. E. Taylor-Clark, M. A. McAlexander, C. Nassenstein, S. A. Sheardown, S. Wilson, J. Thornton, M. J. Carr, and B. J. Undem Relative contributions of TRPA1 and TRPV1 channels in the activation of vagal bronchopulmonary C-fibres by the endogenous autacoid 4-oxononenal J. Physiol., July 15, 2008; 586(14): 3447 - 3459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. W. Lam, J. McDonald, and D. G. Lambert Characterization and comparison of recombinant human and rat TRPV1 receptors: effects of exo- and endocannabinoids Br. J. Anaesth., May 1, 2005; 94(5): 649 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Pomonis, J. E. Harrison, L. Mark, D. R. Bristol, K. J. Valenzano, and K. Walker N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a Novel, Orally Effective Vanilloid Receptor 1 Antagonist with Analgesic Properties: II. In Vivo Characterization in Rat Models of Inflammatory and Neuropathic Pain J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 387 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Walker, L. Urban, S. J. Medhurst, S. Patel, M. Panesar, A. J. Fox, and P. McIntyre The VR1 Antagonist Capsazepine Reverses Mechanical Hyperalgesia in Models of Inflammatory and Neuropathic Pain J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 56 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Undem and M. Kollarik Characterization of the Vanilloid Receptor 1 Antagonist Iodo-Resiniferatoxin on the Afferent and Efferent Function of Vagal Sensory C-Fibers J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 716 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Andersson, M. Adner, E. D. Hogestatt, and P. M. Zygmunt Mechanisms Underlying Tissue Selectivity of Anandamide and Other Vanilloid Receptor Agonists Mol. Pharmacol., September 1, 2002; 62(3): 705 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. CARR, N. M. SCHECHTER, and B. J. UNDEM Trypsin-induced, Neurokinin-mediated Contraction of Guinea Pig Bronchus Am. J. Respir. Crit. Care Med., November 1, 2000; 162(5): 1662 - 1667. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. Szallasi and P. M. Blumberg Vanilloid (Capsaicin) Receptors and Mechanisms Pharmacol. Rev., June 1, 1999; 51(2): 159 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. DAOUI, C. COGNON, E. NALINE, X. EMONDS-ALT, and C. ADVENIER Involvement of Tachykinin NK3 Receptors in Citric Acid-induced Cough and Bronchial Responses in Guinea Pigs Am. J. Respir. Crit. Care Med., July 1, 1998; 158(1): 42 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Fischer, W.-G. Forssmann, and B. J. Undem Nociceptin-Induced Inhibition of Tachykinergic Neurotransmission in Guinea Pig Bronchus, J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 902 - 907. [Abstract] [Full Text]
|
|
|
|
|
|
B. J. Canning, A. Fischer, and B. J. Undem Pharmacological Analysis of the Tachykinin Receptors that Mediate Activation of Nonadrenergic, Noncholinergic Relaxant Nerves that Innervate Guinea Pig Trachealis J. Pharmacol. Exp. Ther., January 1, 1998; 284(1): 370 - 377. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. S. Kim, V. S. McKinnis, K. Adams, and S. R. White Proliferation and repair of guinea pig tracheal epithelium after neuropeptide depletion and injury in vivo Am J Physiol Lung Cell Mol Physiol, December 1, 1997; 273(6): L1235 - L1241. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
